Volume 133, Issue 5



January 31, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Review Series: New Therapeutics for Inherited and Acquired Bleeding Conditions. See the articles in the series.

Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability
This work identifies a novel innate immunity–thrombosis link between activation of the contact system of coagulation involving factor XIIa and kallikrein, promoting neutrophils to release the antimicrobial peptide α-defensin-1, which stabilizes fibrin and inhibits fibrinolysis.

Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment
The authors report how acute myeloid leukemia (AML) blasts can alter the marrow niche by inducing senescence, thus supporting AML survival.

Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL
This Letter to Blood provides evidence that antiviral prophylaxis with tenofovir may be more effective than lamivudine in the prevention of hepatitis B virus–related complications in hepatitis B surface antigen–positive patients with lymphoma who are undergoing R-CHOP therapy.

Introduction to a review series on new therapeutics for inherited and acquired bleeding conditions
The therapeutic management of patients with bleeding disorders is rapidly evolving, with the introduction of multiple new therapeutic options. This series of 5 review articles highlights the increasing number of options available to treat patients with inherited as well as acquired bleeding disorders, enabling the development of approaches that can be tailored to best fit individual patients’ needs.

The articles in this review series include the following:

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.